Different Oral Iron Dosing Regimens in Treatment of Iron Deficency Anemia in Patients With Chronic Kidney Disease

ConditionCKD

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorAssiut University

About this trial

Comparing between the efficacy of alternate day oral iron dose, once daily and thrice daily dose in improving anemia in CKD patients

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All adult patients above 18 years old with CKD stages 2,3 and 4

Disqualifiers

CKD stage 5 (eGFR below 15 ).

Patients with hemolytic anemias.

Chronic liver diseases .

Autoimmune diseases.

Trial population

All adult patients above 18 years old with CKD stages 2,3 and 4

Trial design

Design model

Other

Time perspective

Other

Treatments tested in this trial

Ferrous sulfate
Drug
all patients will receive 200 mg elemental iron (ferrous sulphate)

Treatment groups

150 Participants

are divided into 3 treatment groups

Group A: patients will receive oral iron in alternate day regimen1 intervention

Group B: patients will receive oral iron in single daily dose regimen1 intervention

Group C: patients will receive oral iron in thrice daily dose regimen1 intervention

Trial outcomes

Primary outcomes

Change in Hemoglobin level by gm/dl

Follow up Hemoglobin level in 3 groups

Time frame

6 months

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: